



Tobira Therapeutics Announces Key Management Team Additions

MANALAPAN, NJ – August 8, 2011 – Tobira Therapeutics, Inc. announced the appointment of Helen Jenkins as Senior Vice President, Program Leadership, and Sean M. Dalziel, Ph.D., as Vice President, Pharmaceutical Development.

“Helen and Sean are valuable additions to the Tobira team, and will play integral roles in the development of cenicriviroc, our lead product candidate for the treatment of HIV infection, as we advance it through Phase II clinical studies and prepare for the Phase III program” said Andrew Hindman, President and Chief Executive Officer of Tobira.

Ms. Jenkins brings to Tobira more than 25 years of drug development experience, most recently at Nuon Therapeutics, Inc. and Saegis Pharmaceuticals, where, as a corporate officer, she was responsible for development operations, strategic planning and portfolio management. Prior to Nuon and Saegis, Ms. Jenkins was Senior Director, Product Development/Regulatory Affairs, at Valentis, Inc., where she served as primary liaison with pharmaceutical partners and managed two preclinical gene therapy candidates through IND. Ms. Jenkins also led preclinical programs through successful IND filings during her tenures at Glycomed Inc. and Genentech, Inc. Ms. Jenkins has a Masters of Arts in cellular and molecular biology from San Francisco State University, San Francisco, CA.

Dr. Dalziel brings to Tobira more than 15 years of global experience in the biotechnology, pharmaceutical and chemical industries where he has gained valuable experience in Chemistry Manufacturing and Controls (CMC), strategic planning, and cGMP operations for small- and large-molecule biopharmaceutical development. Prior to joining Tobira, Dr. Dalziel was the first CMC hire at Onyx Pharmaceuticals, where he was the company representative to the FDA and other global health authorities on CMC sections for all pipeline programs, and conducted CMC due diligence in support of business development activities. Dr. Dalziel also held senior positions at Theravance, Inc., where he was the department head of Pharmaceutical Sciences, and at DuPont, where he was involved in the creation of a drug delivery systems business unit. Dr. Dalziel received his Ph.D. in Chemical Engineering from the University of Queensland, Australia, and an MBA from the UC Berkeley Haas School of Business.

Mr. Hindman added: “Tobira’s leadership team continues to evolve as we enhance our company’s depth and breadth. As we have expanded our team, we have opened an office in South San Francisco.”

About Cenicriviroc

Cenicriviroc, Tobira's lead product candidate for the treatment of HIV/AIDS currently being studied in Phase IIb, is a potent antagonist of CCR5, a co-receptor required for HIV infection, and CCR2, a co-receptor involved in the inflammation process that may play a key role in metabolic and cardiovascular diseases. Well-differentiated from available and emerging HIV medicines, cenicriviroc shows promise as a potent, unboosted once-daily oral CCR5 antagonist with potentially important CCR2-mediated anti-inflammatory effects.

Clinical data have been presented at key medical meetings including last summer's International AIDS Conference and the February 2010 and 2011 Conference on Retroviruses and Opportunistic Infections (CROI). Key cenicriviroc data have been published in peer-reviewed journals including the *Journal of Acquired Immune Deficiency Syndromes* (Volume 57, Number 2, June 1, 2011) and *Antimicrobial Agents and Chemotherapy* (Volume 55, Number 6, June 2011).

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV infection. The Company was founded in 2006 by Eckard Weber, MD, a partner at Domain Associates, LLC, a life sciences venture capital firm. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development. For more information, please visit www.tobiratherapeutics.com.

Corporate and Media Relations Contacts:

Felicia Vonella
felicia@vonella.com
917.826.3427

Susan Wolfson
swolfson@tobiratherapeutics.com
917.340.8089

###